REIN
1997
Ramipril Efficacy in Nephropathy
In 352 patients with non-diabetic proteinuric chronic kidney disease, ramipril slowed GFR decline and progression to ESRD compared with placebo.
Result
Primary endpoint: Rate of GFR decline; progression to ESRD
GFR decline 0.53 vs 0.88 mL/min/month (p=0.03); doubling of creatinine or ESRD in 18 (ramipril) vs 40 (placebo), p=0.04.
- Subtopic
- RAAS blockade
- Design
- RCT (stratum with proteinuria ≥3 g/day)
- Enrolled
- 166 patients
- Relevance
- Important: one of several pillars.
- Source
- GISEN Group. Lancet. 1997;349(9069):1857-1863.doi 10.1016/S0140-6736(96)11445-8
Discussion & critique
Extended ACE-inhibitor renoprotection to non-diabetic proteinuric CKD; basis for a 1A guideline recommendation.